We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single Step, Direct ELISA Measures Free Testosterone

By LabMedica International staff writers
Posted on 18 Sep 2012
A single-step direct ELISA measurement of free testosterone saves laboratories time and money while reducing the possibility of errors.

The ability to directly measure free testosterone eliminates the complication of taking multiple indirect measurements and calculating free testosterone through an algorithm. More...
Diagnostic technologies have inherent limitations in terms of both precision and accuracy. Combining multiple procedures worsens these limitations and increases both the cost and opportunity for errors.

The ThunderBolt delivers power and flexibility in a small size. The dual function analyzer provides complete, walk-away automation of 192 patient samples in only a 61 cm by 61 cm space. Completely open architecture allows any enzyme immunoassay (EIA) or clinical laboratory improvement amendments (CLIA) protocol to be programmed. Up to eight different protocols can run in a single batch. Intuitive and robust software further enriches the ThunderBolt, making it the total laboratory automation solution. The ThunderBolt delivers power and flexibility in a small size.

The combination of free and total testosterone gives healthcare professionals more information to make the correct diagnosis when a testosterone-related condition is suspected. Gold Standard Diagnostics (GSD; Davis, CA, USA) also offers an ELISA test for total testosterone level to complement the free testosterone assay.

Total testosterone measures levels of all forms in the blood stream, including: unbound (free), loosely bound to albumin and tightly bound to sex-hormone binding globulin (SHBG). Many common factors influence SHBG levels. As a result, a total testosterone assessment may yield a normal result, but due to higher or lower levels of testosterone-SHBG bonding, the concentration of free testosterone may not correlate directly with total testosterone readings.

SHBG levels can be increased by factors such as obesity and testosterone treatment. Factors that can decrease SHBG levels include aging, pregnancy, and estrogen therapy. Symptoms of low testosterone in males include decreased sexual function, erectile dysfunction, loss of hair, decreased muscle mass, and osteoporosis. For females, symptoms include hot flashes, irritability, decreased libido, and insomnia.

Gold Standard Diagnostics (GSD) provides comprehensive diagnostic solutions that improve lab efficiency and minimize overall costs. Through an extensive product menu, automated instrument platforms, and good customer service, GSD solves laboratory problems.

Related Links:

Gold Standard Diagnostics



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Informatics Platform
CLARION™
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.